Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations

Wilton B. Williams(Duke University), Jinsong Zhang(Duke University), Chuancang Jiang(Duke University), Nathan I. Nicely(Duke University), Daniela Fera(Boston Children's Hospital), Kan Luo(Duke University), M. Anthony Moody(Duke University), Hua‐Xin Liao(Jinan University), S. Munir Alam(Duke University), Thomas B. Kepler(Boston University), Akshaya Ramesh(Boston University), Kevin Wiehe(Duke University), James A. Holland(Duke University), Todd Bradley(Duke University), Nathan Vandergrift(Duke University), Kevin O. Saunders(Duke University), Robert Parks(Duke University), Andrew Foulger(Duke University), Shi-Mao Xia(Duke University), Mattia Bonsignori(Duke University), David C. Montefiori(Duke University), Mark K. Louder(National Institute of Allergy and Infectious Diseases), Amanda Eaton(Duke University), Sampa Santra(Boston Children's Hospital), Richard M. Scearce(Duke University), Laura L. Sutherland(Duke University), Amanda Newman(Duke University), Hilary Bouton-Verville(Duke University), Cindy Bowman(Duke University), Howard M. Bomze(Duke University), Feng Gao(Duke University), Dawn J. Marshall(Duke University), John F. Whitesides(Duke University), Xiaoyan Nie(Duke University), Garnett Kelsoe(Duke University), Steven G. Reed(Infectious Disease Research Institute), Christopher B. Fox(Infectious Disease Research Institute), Kim Clary(Infectious Disease Research Institute), Marguerite Koutsoukos(GlaxoSmithKline (Belgium)), David Franco(GlaxoSmithKline (Belgium)), John R. Mascola(National Institute of Allergy and Infectious Diseases), Stephen C. Harrison(Boston Children's Hospital), Barton F. Haynes(Duke University), Laurent Verkoczy(Duke University)
Nature Communications
November 17, 2017
Cited by 90Open Access
Full Text

Abstract

Abstract A strategy for HIV-1 vaccine development is to define envelope (Env) evolution of broadly neutralizing antibodies (bnAbs) in infection and to recreate those events by vaccination. Here, we report host tolerance mechanisms that limit the development of CD4-binding site (CD4bs), HCDR3-binder bnAbs via sequential HIV-1 Env vaccination. Vaccine-induced macaque CD4bs antibodies neutralize 7% of HIV-1 strains, recognize open Env trimers, and accumulate relatively modest somatic mutations. In naive CD4bs, unmutated common ancestor knock-in mice Env + B cell clones develop anergy and partial deletion at the transitional to mature B cell stage, but become Env − upon receptor editing. In comparison with repetitive Env immunizations, sequential Env administration rescue anergic Env + (non-edited) precursor B cells. Thus, stepwise immunization initiates CD4bs-bnAb responses, but immune tolerance mechanisms restrict their development, suggesting that sequential immunogen-based vaccine regimens will likely need to incorporate strategies to expand bnAb precursor pools.


Related Papers

No related papers found

Powered by citation graph analysis